Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F17%3AN0000050" target="_blank" >RIV/00027162:_____/17:N0000050 - isvavai.cz</a>

Result on the web

<a href="http://link.springer.com/article/10.1007%2Fs00262-016-1932-4" target="_blank" >http://link.springer.com/article/10.1007%2Fs00262-016-1932-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00262-016-1932-4" target="_blank" >10.1007/s00262-016-1932-4</a>

Result language

angličtina

Original language name

Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

Original language description

The natural adjuvant properties of bacterial ghosts (BGs) lie within the presence of intact pathogen-associated molecular patterns on their surface. BGs can improve the direct delivery, natural processing and presentation of target antigens within dendritic cells (DCs). Moreover, sensitization of human DCs by cancer cell lysate (oncolysate)-loaded BGs in the presence of IFN-α and GM-CSF enhanced DC maturation as indicated by an increased expression of maturation markers and co-stimulatory molecules, higher production of IL-12p70 and stimulation of significantly increased proliferation of both autologous CD4+ and CD8+ T cells compared to DCs matured in the presence of purified lipopolysaccharide. The induced T cells efficiently recognized oncolysate-derived tumor-associated antigens expressed by cancer cells used for the production of oncolysate. Our optimized one-step simultaneous antigen delivery and DC maturation-inducing method emerges as a promising tool for the development and implementation of next-generation cellular cancer immunotherapies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30401 - Health-related biotechnology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancer Immunology Immunotherapy

ISSN

0070-217X

e-ISSN

—

Volume of the periodical

66

Issue of the periodical within the volume

2

Country of publishing house

DE - GERMANY

Number of pages

11

Pages from-to

149-159

UT code for WoS article

000394982400002

EID of the result in the Scopus database

—